Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels

BEAM-302 is Beam’s lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease.Data Show AAT Levels Above Protective ThresholdThe company announced updated safety and efficacy data from its ongoing Phase 1/2 trial of BEAM-302, highlighting that treatment with ...